Polarean Imaging Share Discussion Threads

[moontheloon] 08/5/2024 08:51

I don't understand your concern if you're not invested... you're only investing your most important asset.... your lifespan wasted on a company you don't invest in.

[moontheloon] 08/5/2024 08:49

Its never enough nigel. World class tech gets customers its obvious this years budgets just beginning working through. You'd say it's just not enough if we had 5 in a row.

[nigelpm] 08/5/2024 08:25

It's just not enough. Continuing to watch with interest as the tech is world class but as it stands the equity is worthless.

[moontheloon] 08/5/2024 07:47

Nigel we only had commercial news of 2 institutions using the tech and buying the latest kit on top of a previous one as an early adopter just last week.. the next one will push us on and even the most pathetic and desperate will start to realise the traction. Duke next... is nailed on. But will it be next.

[moontheloon] 08/5/2024 07:43

I'm sure the event and delegates will see truth more than the panicky shorting no mark. Would be very outlandish to provide shareholders with clear information about an event and actually lie? Maybe lying is inherent in your life... and its ingrained? and you are now blatantly saying black is white. Give it a rest maybe find a company you wish to invest in and doesn't trigger this pathetic behaviour

[nigelpm] 08/5/2024 07:31

Featured presentation. Where is the sales and commercial news?

[purchaseatthetop] 08/5/2024 07:26

Sorry but they haven’t



They are a poster presenting company but no mention of featured.

[moontheloon] 08/5/2024 07:14

The prominence and obvious high esteem our tech is bestowed with. And so many additional applications and avenues for partnership and business...Christopher von Jako, Ph.D., CEO of Polarean, said: "We are delighted to have been selected as a featured company at The Respiratory Innovation Summit, which is testament to the value of our XENOVIEW technology being recognised across lung clinicians and pulmonary drug developers. The RIS and the ATS annual conference serve as invaluable venues to spotlight our Xenon MRI platform, especially to those enthusiastic about fostering collaborative partnerships. These events provide an unparalleled opportunity to elevate awareness of our technology among clinicians, regulators, investors, and potential pharmaceutical industry partners.

[sandy12345] 08/5/2024 07:14

Excellent news!!

[moontheloon] 07/5/2024 08:17

I also notice there is a world training course centering around polarean technology being held in Denmark. The awareness and growth of this awareness is a tipping point. As we can see from Cincinnati this years budgets with red tape time thrown in... gets us this qtr onwards for more system uptake announcements. Happy to hold and add. Duke very close, might not even be the next announcement though.

[moontheloon] 07/5/2024 08:12

For clarity. Will help the guessers. And also covering two institutions, and with nukem happily increasing stake to one of the largest shareholders. Know what they're supplying and the pipeline I know who I believe!A guessing no mark on advfn or the supplier of gas and 10%+ shareholder in polarean who have also committed to the next capital addition in whatever non dilutive form it takes. Dyor people. The AIM-traded firm said Cincinnati Children's, ranked as the top children's hospital in the United States for 2023-2024 by US News & World Report, previously acquired the first clinical polariser, and was dedicated to advancing Xenon MRI for challenging lung diseases.It said the hospital conducts clinical imaging for both children and adults, including patients from their partner institution, UC Medical Centre.Under the leadership of Dr Jason Woods, Cincinnati Children's operates a research programme centred on the Xenon MRI platform technology."I commend the ongoing work of the entire team at Cincinnati Children's, both in research and clinical care," said Polarean chief executive officer Christopher von Jako."They consistently recognise the benefits that pulmonary functional Xenon MRI technology offers to children with chronic lung disease and have extended access to this technology to the adjacent adult hospital."We look forward to working closely with their team to ensure a swift implementation of the new system."

[purchaseatthetop] 07/5/2024 06:31

26/4/23 RNS

First order for XENOVIEWTM gas blend received from Cincinnati Children's Hospital Medical Center
Clinical cylinder sale marks key milestone and execution of commercial plan

3/5/24 RNS

Polarean Imaging Plc (AIM: POLX), a commercial-stage medical device leader in advanced Magnetic Resonance Imaging ("MRI") of lung function, announces that it has received an order for a new polariser to replace the research polariser at Cincinnati Children's Hospital Medical Center ("Cincinnati Children's").

That’s the trouble. One year on and no other sales and this is simply a replacement of an old research machine.

[moontheloon] 07/5/2024 05:58

https://www.sharecast.com/news/aim-bulletin/polarean-gets-new-polariser-order-from-cincinnati-childrens--16712953.html

[bones698] 05/5/2024 13:47

Chart pints to what most know is coming. A placing in th near future. Might aswell wait for that if you want to get in lower and think the company has a future.

[moontheloon] 05/5/2024 09:57

Expanding the use to a younger age group of children is the expansion of the fda they will easily achieve. Effectively doubling the cases to analyse. This isnt a patch this is another machine. The use is across two institutions, so 2 sites, another effective doubling of cases. I hope this helps with the maths. Thanks please come again (don't)Plenty more of these coming, Duke is just being budgeted for. I know this.

[purchaseatthetop] 05/5/2024 09:22

It’s research.

“Dr. Jason Woods, Director of Research in Pulmonary Medicine at Cincinnati Children's said: "We are excited to enhance our research capabilities with Polarean's latest technology. This upgrade will allow us to further explore the applications of Xenon MRI in paediatric pulmonary care and expand our current clinical offerings for the benefit of our patients."

It will be worth almost nothing.

[bones698] 03/5/2024 08:15

No money mentioned so minimal and cash raise coming could be at 1 or 2p here soon. Think I'd wait for that to happen before even thinking of buying here

[moontheloon] 03/5/2024 08:11

So in effect this is now 2 institutions in this rns. This will move nicely when people cotton on to value. Vs risk reward.

[moontheloon] 03/5/2024 07:55

Sounds like the kit is a great addition to any institute but is being improved continuously... via Duke and other research.Can't wait for gas exchange to be added to the fda roster. All for a less than 8m MC

[moontheloon] 03/5/2024 07:51

Just one of several In process. Gla.Particularly shorters. This is the start they take a lot of working through the red tapes and budgets but work through they will.Duke conversion will be close on the heels

[moontheloon] 03/5/2024 07:48

Polarean Imaging PLC Order received for upgraded hyperpolariserSource: RNS Regulatory News?RNS Number : 0929NPolarean Imaging PLC03 May 2024 Polarean Imaging Plc("Polarean" or the "Company") Order received for upgraded hyperpolariserCincinnati Children's Hospital Medical Center upgrades their existing research system to provide additional flexibility for research and clinical scanning Polarean Imaging Plc (AIM: POLX), a commercial-stage medical device leader in advanced Magnetic Resonance Imaging ("MRI") of lung function, announces that it has received an order for a new polariser to replace the research polariser at Cincinnati Children's Hospital Medical Center ("Cincinnati Children's"). Cincinnati Children's is ranked as the number one children's hospital for 2023/2024 in the United States by U.S. News & World Report. Cincinnati Children's previously purchased the first clinical polariser and continues to demonstrate a commitment to the future of Xenon MRI for challenging lung diseases. Cincinnati Children's performs hospital clinical imaging on both children and adults (from their neighbouring partner institution, UC Medical Centre). Led by Dr. Jason Woods, the hospital runs a robust research programme focused on the Xenon MRI platform technology. The new polariser will enable Cincinnati Children's to leverage the benefits of cutting-edge technology and providing flexibility to expand XENOVIEW™ capabilities for their research and clinical patients.Christopher R. von Jako, Ph.D., CEO of Polarean, said: "I commend the ongoing work of the entire team at Cincinnati Children's, both in research and clinical care. They consistently recognise the benefits that pulmonary functional Xenon MRI technology offers to children with chronic lung disease and have extended access to this technology to the adjacent adult hospital. We look forward to working closely with their team to ensure a swift implementation of the new system."Dr. Jason Woods, Director of Research in Pulmonary Medicine at Cincinnati Children's said: "We are excited to enhance our research capabilities with Polarean's latest technology. This upgrade will allow us to further explore the applications of Xenon MRI in paediatric pulmonary care and expand our current clinical offerings for the benefit of our patients."Enquiries:Polarean Imaging plcwww.polarean.com / www.polarean-ir.comChristopher von Jako, Ph.D, Chief Executive OfficerVia Walbrook PRCharles Osborne, Chief Financial OfficerStifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker)[phone]Nicholas Moore / Samira Essebiyea / Kate Hanshaw (Healthcare Investment Banking)Nick Harland (Corporate Broking)Walbrook PRTel: [phone] or [e-mail] Dunphy / Phillip MarriageMob: [phone] / [phone] About PolareanPolarean is a revenue-generating medical imaging technology company revolutionizing pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW™, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information about Polarean, please visit www.polarean.com.XENOVIEW IMPORTANT SAFETY INFORMATION  IndicationXENOVIEW™, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 12 years and older. Limitations of UseXENOVIEW has not been evaluated for use with lung perfusion imaging. CONTRAINDICATIONSNone. Warnings and PrecautionsRisk of Decreased Image Quality from Supplemental Oxygen: Supplemental oxygen administered simultaneously with XENOVIEW inhalation can cause degradation of image quality. For patients on supplemental oxygen, withhold oxygen inhalation for two breaths prior to XENOVIEW inhalation, and resume oxygen inhalation immediately following the imaging breath hold. Risk of Transient Hypoxia: Inhalation of an anoxic gas such as XENOVIEW may cause transient hypoxemia in susceptible patients. Monitor all patients for oxygen desaturation and symptoms of hypoxemia and treat as clinically indicated. Adverse Reactions Adverse Reactions in Adult Patients: The adverse reactions (> one patient) in efficacy trials were oropharyngeal pain, headache, and dizziness.  Adverse Reactions in Pediatric and Adolescent Patients: In published literature in pediatric patients aged 6 to 18, transient adverse reactions were reported: blood oxygen desaturation, heart rate elevation, numbness, tingling, dizziness, and euphoria. In at least one published study of pediatric patients aged 6 to 18 years, transient decrease in SpO2% and transient increase in heart rate was reported following hyperpolarized xenon Xe 129 administration. XENOVIEW is not approved for use in pediatric patients less than 12 years of age.

[wetdream] 17/4/2024 09:11

Aren’t they using Phillips sales force?
Also, surely the research hospitals’ contracts specify a fixed time period for deciding to go ahead on a commercial basis or return the technology to POLX?

[henley2] 17/4/2024 08:18

New budget year started in January, makes you wonder what the Polarean sales force do all day, or perhaps they’re just not up to the job of selling expensive medical equipment. Clock continues to tick and the cash runway is coming to an end in 6 months. Look forward to seeing whether the CEO has the bottle to come to the UK this year for the AGM to face shareholders.

[henley2] 17/4/2024 08:10

If the technology is so great, why is it taking so long to convert the research centres to commercial terms? These centres are the early adopters of the technology and more than 15 months post FDA approval….NADAH!

[moontheloon] 16/4/2024 08:49

Got a jv in the wings for this . That's the next ingredient for real traction . what amazing technology!